Autologous hematopoietic cell transplantation (HCT) may be considered medically necessary in patients with primary refractory or relapsed Hodgkin lymphoma.
Allogeneic HCT, using either myeloablative or reduced-intensity conditioning regimens, may be considered medically necessary in patients with primary refractory or relapsed Hodgkin lymphoma.
Second autologous HCT for relapsed lymphoma after a prior autologous HCT is considered investigational.
Tandem autologous HCT is considered investigational in patients with Hodgkin lymphoma.
Other uses of HCT in patients with Hodgkin lymphoma are considered investigational, including, but not limited to, initial therapy for newly diagnosed disease to consolidate a first complete remission.
